European Pharmaceutical Review

JUNE 24, 2022

But what are the key potential changes and how could they impact drug developers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

European Pharmaceutical Review

SEPTEMBER 14, 2023

In 2001 and 2007, through 2009, the economy was hit hard. There was a significant slowdown in drug development, clinical trials, and new drugs coming to market. EMA prepares for winter antibiotic shortages That slowdown resulted in 211 drug shortages in 2010—the highest number recorded in a single year at the time.

Drug Development 98

Drug Development Drug Pricing Communication 98

Express Pharma

SEPTEMBER 17, 2024

With an aim to become more value-driven, India’s pharma industry is looking beyond generics, targeting innovations in drug development. Students here lack the basic English communication skills and require direction on career options,” highlighting the need to improve skilling in institutes at the tier-2 and tier-3 levels.

Communication 105

Communication Drug Development 105

Pharmaceutical Technology

FEBRUARY 23, 2023

As formulators, we are often able to directly impact the amount of drug absorbed through formulation optimization and improve exposure. However, the chances of improving the exposure profile of a drug that is highly cleared by formulation modification are limited. S54 – S61 (2001).

Drug Development 98

Drug Development Compounding Dosage Packaging 98

Pharmaceutical Technology

MAY 3, 2023

from 2001 to 2022.” In 2017, FDA announced the Drug Competition Action Plan (DCAP) to allow consumers to get access to medicines. She says in those cases the FDA applies a multiple first-applicant approach to eligibility for 180-day exclusivity. However, that percentage of multiple first generics is not very high—approximately 10.6%

Generic Medicine 98

Generic Medicine Drug Development Communication Diabetes 98

Pharmaceutical Technology

FEBRUARY 28, 2023

Orphan drug development is expanding Change is happening. 1983 was a pivotal year for the rare disease community, with the US Food and Drug Administration’s introduction of the Orphan Drug Act. With similar incentives offered by EU/EEA and UK law, orphan drug development has taken off.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development Communication 52

Pharmaceutical Technology

FEBRUARY 20, 2023

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.

Vaccines 52

Vaccines Communication Immunity Immunization 52